Special Issue "Kinases and Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 31 March 2014
Dr. Jonas Cicenas
CALIPHO Group, Swiss Institute of Bioinformatics, CMU - 1, rue Michel Servet, CH-1211 Geneva 4, Switzerland
Phone: +41 22 379 58 74
Fax: +41 22 379 58 58
Interests: breast cancer; prostate cancer; acute myeloid leukemia (AML); kinases
Protein phosphorylation is one of the most critical mechanisms for regulating various cellular functions. Consequently, protein kinase dysfunctions have been associated with the development of various types and subtypes of human cancers. Some examples include amplification and overexpression of the epidermal growth factor receptor (EGFR) and the ERBB2 receptor in lung and breast tumors, mutation of the BRAF oncogene in a wide range of human tumors, and the chromosomal translocation known as the Philadelphia chromosome, which results in ABL1 tyrosine kinase activation.
In the drug discovery field, despite early skepticism on the potential and selectivity of protein kinase inhibitors, enormous progress has been made. New classes of drugs, such as antibodies to receptors, and small-molecule inhibitors, were developed and tested in the clinics. The success of such drugs (e.g., imatinib and trastuzumab) encouraged development of new, second-generation drugs, which target protein kinases in cancer. Moreover, kinases have been shown to be invaluable diagnostic, prognostic, and predictive biomarkers for many types of cancers. In addition to protein kinases, lipid kinases, such as phosphatidylinositol-3-kinase (PI3K) and phosphatidylinositol-4-kinase (PI4K), have also been involved in the pathology of many tumors. In this issue of Cancers, “Kinases and Cancers”, experts are invited to contribute original research papers or review articles that will provide further insights on the various functions of kinases in cancers, and on their role as drug targets and biomarkers.
Dr. Jonas Cicenas (EMB of Cancers)
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed Open Access quarterly journal published by MDPI.
- kinase inhibitors in cancer therapy
- monoclonal antibodies against kinases in cancer therapy
- kinases as oncogenes
- kinases as tumor supressors
- kinases as biomarkers
- protein phosphorylation and cancer
Last update: 22 August 2013